Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5362 - Trends in Incidence and Survival Analyses of Adult-onset Medulloblastoma


28 Sep 2019


Poster Display session 1


Tumour Site

Central Nervous System Malignancies


Feifei Lin


Annals of Oncology (2019) 30 (suppl_5): v143-v158. 10.1093/annonc/mdz243


F. Lin1, Q. Zhuang1, X. Lin1, X. Zhang1, Y. Huang1, L. Tang1, W. Junxin1, J. Li2

Author affiliations

  • 1 Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, 350014 - Fuzhou/CN
  • 2 Radiation, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, 361003 - Xiamen/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5362


Medulloblastoma (MB) is a rare central nervous system malignancy in adult. For its rarity, most previous studies are limited on patient populations and ascertainment bias. We aimed to explore the population-level trends in incidence and assess potential predictors of overall survival (OS).


We utilized the Surveillance, Epidemiology and End Results Program (SEER) database between 1973 and 2015, to estimate the epidemiological trends of adult MB in the United States. Propensity-score matching was used to balance potential selection biases and Cox proportional hazard modeling was used to determine predictors of OS.


The age-adjusted incidence was stable in MB patients aged 20 years old and elder in total (annual percent change (APC)=0.15). The age-adjusted incidence rate in males was slightly higher than that in females (0.065 vs. 0.049 per 100,000). Compared to whites, the rate was nearly doubled to blacks (0.063 vs. 0.033 per 100,000). There was obvious differ between the younger group and the elder group (aged 20-39: 0.107 vs. aged≥40: 0.025 per 100,000). According to multivariable Cox analysis, age (P < 0.001) and surgical resection (P = 0.002) were independently prognostic factors. Moreover, subgroup analysis showed that the benefits of radiotherapy (P = 0.048) and chemotherapy (P = 0.045) were observed in the patients without gross total resection (GTR). After propensity-score matching (n = 582), factors impacting OS were age (P < 0.001), surgical resection (P = 0.012), histology (P = 0.031), insurance status (P = 0.014) and marital status(P = 0.040).


From the SEER database, race, gender and age disparities were found in incidence of adult MB patients. The survival analysis demonstrated the benefits of the GTR and younger patients. As for patients without GTR, radiotherapy and chemotherapy may improve the long-term survival.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Feifei, Lin.


The Fujian Province Natural Science Foundation (2017J01260), Joint Funds for the Innovation of Science and Technology, Fujian province (2017Y9074), and the Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education/Beijing (2017 Open Project-9).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.